Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and

C J Burd1, C E Petre, H Moghadam

  • 1Department of Cell Biology, University of Cincinnati College of Medicine, P.O. Box 670521, 3125 Eden Avenue, Cincinnati, Ohio 45267-0521, USA.

Insights

Cyclin D1 represses prostate cancer

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Endocrinology

Background:

  • The androgen receptor (AR) is crucial for prostate cancer progression.
  • Cyclin D1 is a known corepressor of the AR.
  • Previous understanding of cyclin D1's repressive function was incomplete.

Purpose of the Study:

  • To investigate novel mechanisms of cyclin D1-mediated repression of the AR.
  • To elucidate the specific interactions between cyclin D1 and the AR.

Main Methods:

  • Investigated cyclin D1 binding to the AR N-terminal domain.
  • Utilized AR mutant lacking the 23FxxLF27 motif.
  • Assessed AR activity and interactions following cyclin D1 modulation.

Main Results:

  • Cyclin D1 binds the AR N-terminal domain via the 23FxxLF27 motif.
  • This binding disrupts AR amino-carboxy terminal interactions.
  • Deletion of the binding site impairs AR activity and reveals C-terminal repression.

Conclusions:

  • Cyclin D1 employs a novel mechanism to repress AR activity by modulating its terminal interactions.
  • This specific interaction is critical for AR modulation in prostate cancer.
  • Identified new therapeutic targets for prostate cancer treatment.

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...